Table 4.
Summary of main results using randomised controlled trials only and intention to treat sample: meta-analyses and network meta-analyses
| Treatment comparison, reference | No of studies (No of patients) | Study group (No of events/total No) | Odds ratio from direct and indirect comparisons (95% CrI) (95% PrI indirect comparison only) | Risk ratio | Vaccine efficacy % (95% CrI) | ||
|---|---|---|---|---|---|---|---|
| Treatment | Control | Direct comparison (meta-analysis) (95% CrI) | Indirect comparison (95% CrI) (95% PrI) | ||||
|
Doctor or laboratory confirmed herpes zoster cases:
5 RCTs, 90 605 participants, average follow-up 28 (range 2-44) months | |||||||
| HZ/su v ZVL | — | — | — | 0.15 (0.02 to 0.68) (0.01 to 1.42)* | — | 0.15 (0.02 to 0.69) (0.01 to 1.41)* | 85 (31 to 98)* |
| HZ/su v placebo56 62 78 | 2 (29 311) | 32/14 648 | 458/14 663 | 0.06 (0.02 to 0.21)* | 0.06 (0.02 to 0.21)* | — | 94 (79 to 98)* |
| ZVL v placebo10 11 70 80-87 | 3 (61 294) | 346/30 688 | 741/30 606 | 0.43 (0.15 to 1.63) | 0.43 (0.16 to 1.61) | — | 57 (−61 to 84) |
| Common within network between study variance | — | — | — | — | 0.37 (0.02 to 3.02) | 0.37 (0.02 to 3.10) | — |
|
Suspected herpes zoster cases:
7 RCTs, 91 840 participants, average follow-up 20 (range 1-44) months | |||||||
| HZ/su v ZVL | — | — | — | 0.37 (0.20 to 0.57) (0.16 to 0.71)* | — | 0.37 (0.20 to 0.57) (0.16 to 0.71)* | 63 (43 to 80)* |
| HZ/su v placebo56 62 78 | 2 (29 311) | 150/14 648 | 643/14 663 | 0.23 (0.15 to 0.33)* | 0.23 (0.16 to 0.34)* | — | 77 (66 to 84)* |
| ZVL v placebo10 11 61 66 70 80-87 | 5 (62 529) | 597/31 307 | 1000/31 222 | 0.60 (0.47 to 0.93)* | 0.61 (0.48 to 0.93)* | — | 39 (7 to 52)* |
| Common within network between study variance | — | — | — | — | 0.01 (0.00 to 0.46) | 0.01(0.00 to 0.49) | — |
|
Herpes zoster ophthalmicus cases:
2 RCTs, 14 209 participants, average follow-up 25 (range 2-60) months | |||||||
| HZ/su v placebo†56 78 | 1 (13 900) | 1/6950 | 6/6950 | 0.12 (0.00 to 0.84)* | 0.12 (0.00 to 0.84)* | - | 88 (16 to 100)* |
| ZVL v placebo†70 | 1 (309) | 1/207 | 0/102 | 2.57 (0.08 to 1293.66) | 2.57 (0.08 to 830.34) | — | −157 (−129266 to 92) |
| Common within network between study variance | — | — | — | — | 0.48 (0.00 to 5.07) | — | — |
|
Post-herpetic neuralgia:
2 RCTs, 52 446 participants, average follow-up 26 (range 6-46) months | |||||||
| HZ/su v placebo†56 78 | 1 (13 900) | 4/6950 | 28/6950 | 0.13 (0.04 to 0.35)* | 0.13 (0.04 to 0.35)* | — | 87 (65 to 96)* |
| ZVL v placebo†10 80-86 | 1 (38 546) | 27/19 270 | 80/19 276 | 0.33 (0.21 to 0.51)* | 0.34 (0.21 to 0.51)* | — | 66 (49 to 79)* |
| Common within network between study variance | — | — | — | — | 0.46 (0.00 to 4.93) | — | — |
CrI=credible interval; PrI=prediction interval; RCT=randomised controlled trial; HZ/su=herpes zoster adjuvant recombinant subunit vaccine; ZVL=herpes zoster live attenuated vaccine.
*
P<0.05.
†
Only one study included in comparison.